Patients & products

We enable people with life-altering conditions to lead better lives.
That's a brave claim, but it's one that inspires everyone at Shire. By harnessing that energy and dedication, we can make a real difference to patients and their families.

VYVANSE

VYVANSE Revenues have reached $319 million this year.

Llalda / XL

LIALDA / MEZAVANT XL US ASA market share is now 14.1% as at December 2008

FOSRENOL

FOSRENOL Is approved in 42 countries and is now available in Japan.

ELAPRASE

ELAPRASE Is now approved and launched in 43 countries.

Replagal

REPLAGAL Has had revenue growth of 22%.

FIRAZYR

FIRAZYR Has been launched and is now available in the UK, Germany and Austria.